Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for isolated segmental infantile hemangioma has been reported in the published literature.
No clinical trials have been registered for isolated segmental infantile hemangioma.
3 publications have been identified in PubMed for isolated segmental infantile hemangioma. Research spans Diagnostic / Biomarker (33%), Case Report / Case Series (33%), and Epidemiology / Natural History (33%).
Metry DW (2025). [PMID: 40192237](https://pubmed.ncbi.nlm.nih.gov/40192237/). *Mol Genet Genomic Med*. [Epidemiology / Natural History]
Ripetta L (2024). [PMID: 39677193](https://pubmed.ncbi.nlm.nih.gov/39677193/). *Cureus*. [Case Report / Case Series]
Neri I (2024). [PMID: 39122516](https://pubmed.ncbi.nlm.nih.gov/39122516/). *Dermatol Pract Concept*. [Diagnostic / Biomarker]
Data assembled from 3 of 12 sources · Last updated Nov 3, 2026, 8:27 AM UTC
European rare disease database
AI-curated news mentioning isolated segmental infantile hemangioma
Updated Oct 7, 2026
Arkayli Biopharma has received FDA's 'Study May Proceed' response for its IND application and a $2.98 million SBIR grant from NIH to advance ARK001 for infantile hemangioma. The company is set to initiate a Phase 1B clinical trial to evaluate the safety of this non-systemic treatment.